Initially, primary genetic testing was limited to the high penetrance genes BRCA1 and/or BRCA2, which account for approximately 3–5% of breast cancers and 12–15% of ovarian cancers in most populations (Balmaña et al., 2011; Lang et al., 2017; Li et al., 2019). This evidence concerns the gene BRCA1 and ovarian carcinoma.